{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ocrelizumab-matching+placebo", "query": { "intervention": "Ocrelizumab-matching placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T17:16:35.312Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00406419", "title": "A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "ocrelizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1015, "start_date": "2006-12-27", "completion_date": "2015-04-22", "has_results": true, "last_update_posted_date": "2020-11-27", "last_synced_at": "2026-09-29T17:16:35.312Z", "location_count": 1, "location_summary": "South San Francisco, California", "locations": [ { "city": "South San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00406419" }, { "nct_id": "NCT00676715", "title": "A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Avonex", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 220, "start_date": "2008-07-17", "completion_date": "2023-11-08", "has_results": true, "last_update_posted_date": "2024-12-31", "last_synced_at": "2026-09-29T17:16:35.312Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Berkeley, California • San Francisco, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00676715" }, { "nct_id": "NCT01194570", "title": "A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis, Primary Progressive" ], "interventions": [ { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 735, "start_date": "2011-03-02", "completion_date": "2022-12-31", "has_results": true, "last_update_posted_date": "2024-01-10", "last_synced_at": "2026-09-29T17:16:35.312Z", "location_count": 37, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Phoenix, Arkansas + 31 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01194570" }, { "nct_id": "NCT00476996", "title": "A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Leflunomide", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 836, "start_date": "2007-05-15", "completion_date": "2018-05-14", "has_results": true, "last_update_posted_date": "2019-08-12", "last_synced_at": "2026-09-29T17:16:35.312Z", "location_count": 144, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00476996" }, { "nct_id": "NCT03835728", "title": "Efficacy of Ocrelizumab in Autoimmune Encephalitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autoimmune Encephalitis" ], "interventions": [ { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2019-01-22", "completion_date": "2020-10-02", "has_results": true, "last_update_posted_date": "2021-10-19", "last_synced_at": "2026-09-29T17:16:35.312Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03835728" }, { "nct_id": "NCT01412333", "title": "A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis" ], "interventions": [ { "name": "Interferon beta-1a", "type": "DRUG" }, { "name": "Ocrelizumab-matching placebo", "type": "DRUG" }, { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Interferon beta-1a-matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 835, "start_date": "2011-09-20", "completion_date": "2022-12-30", "has_results": true, "last_update_posted_date": "2024-03-08", "last_synced_at": "2026-09-29T17:16:35.312Z", "location_count": 48, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 43 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01412333" }, { "nct_id": "NCT01247324", "title": "A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis" ], "interventions": [ { "name": "Interferon beta-1a", "type": "DRUG" }, { "name": "Ocrelizumab-matching placebo", "type": "DRUG" }, { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Interferon beta-1a-matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 821, "start_date": "2011-08-31", "completion_date": "2022-12-31", "has_results": true, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-09-29T17:16:35.312Z", "location_count": 40, "location_summary": "Phoenix, Arizona • Carmichael, California • La Jolla, California + 32 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Carmichael", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01247324" }, { "nct_id": "NCT04035005", "title": "A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis, Primary Progressive" ], "interventions": [ { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1013, "start_date": "2019-08-12", "completion_date": "2028-01-19", "has_results": true, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-09-29T17:16:35.312Z", "location_count": 8, "location_summary": "Washington D.C., District of Columbia • Clearwater, Florida • Orlando, Florida + 5 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Vero Beach", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04035005" }, { "nct_id": "NCT05123703", "title": "A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing-remitting Multiple Sclerosis" ], "interventions": [ { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Ocrelizumab Placebo", "type": "OTHER" }, { "name": "Fingolimod", "type": "DRUG" }, { "name": "Fingolimod Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "10 Years to 17 Years" }, "enrollment_count": 188, "start_date": "2022-05-19", "completion_date": "2029-09-17", "has_results": true, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-09-29T17:16:35.312Z", "location_count": 10, "location_summary": "La Jolla, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05123703" }, { "nct_id": "NCT04544449", "title": "A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis, Primary Progressive" ], "interventions": [ { "name": "Fenebrutinib", "type": "DRUG" }, { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Placebo matched to ocrelizumab", "type": "DRUG" }, { "name": "Placebo matched to fenebrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 985, "start_date": "2020-10-26", "completion_date": "2027-07-21", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-09-29T17:16:35.312Z", "location_count": 43, "location_summary": "Homewood, Alabama • Berkeley, California • Fullerton, California + 40 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Berkeley", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Sunnyvale", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04544449" } ] }